/
Pharmaceutical preparations company · FL · FY ends Mar · Revenue $35M · 86.92% margin · $3M FCF
Margins and capital returns are both well above average: 60.83% operating margin, ROIC at 607.38%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 177.1% YoY with margins expanding 53.4pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$35M
▲ +177.1% YoY
Net Income (TTM)
$4M
▲ +300.6% YoY
Op. Margin
86.92%
▲ +53.4pp YoY
ROIC
481.10%
▲ +569.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3M
▲ +270.6% YoY
Op. Cash Flow (TTM)
$3M
▲ +262.5% YoY
Net Debt
-$276K
Net Cash Position
Cash & Equiv.
$416K
5Y CAGR: +129.0%
Continue Research